microRNA-based diagnostic and therapeutic
opportunities in lung cancer

• Authors: Jianfei Zhao , Yan Cai , Xi Liu
• Languages of publication: EN

Abstracts

EN

microRNAs (miRNAs) are a class of non-coding
RNA which suppress target gene expression. miRNAs are
involved in most physiological and pathological process,
including carcinogenesis. miRNA expression profiles help to
improve lung cancer diagnosis, classification and prognostic
information. Tumor suppressive and oncogenic miRNAs have
been discovered and their functions have been investigated.
Emphasis is placed on the development of miRNA-based
methods for lung cancer diagnosis and therapy and future
directions are proposed.

Keywords

EN

miRNA; lung cancer; diagnosis; prognosticinformation; therapy

• Publisher: De Gruyter Open
• Journal: microRNA Diagnostics and Therapeutics
• Year: 2014
• Volume: 1
• Issue: 1

Dates

received

12 - 4 - 2014

accepted

23 - 11 - 2014

online

29 - 4 - 2015

Contributors

author

Jianfei Zhao

• Laboratory of Metabolism, Center for Cancer
  Research, National Cancer Institute, National Institutes of Health,
  Bethesda, MD 20892, USA

author

Yan Cai

• Laboratory of Metabolism, Center for Cancer
  Research, National Cancer Institute, National Institutes of Health,
  Bethesda, MD 20892, USA

author

Xi Liu

• Department of Thoracic and Head&Neck
  Medical Oncology, University of Texas MD Anderson Cancer Center,
  Houston, TX 77030, USA

References

• [1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CACancer J Clin 2012;62:10-29.
• [2] Shopland DR. Tobacco use and its contribution to early cancermortality with a special emphasis on cigarette smoking.Environ Health Perspect 1995;103 Suppl 8:131-42.[Crossref]
• [3] Travis WD. Pathology of lung cancer. Clin Chest Med2002;23:65-81, viii.[Crossref]
• [4] Schiller JH. Current standards of care in small-cell andnon-small-cell lung cancer. Oncology 2001;61 Suppl 1:3-13.[Crossref]
• [5] Witt BL, Wallander ML, Layfield LJ, Hirschowitz S. Respiratorycytology in the era of molecular diagnostics: a review. DiagnCytopathol 2012;40:556-63.[Crossref]
• [6] Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCPevidence-based clinical practice guidelines (2nd edition). Chest2007;132:131S-48S.[Crossref]
• [7] Travis WD, Brambilla E, Noguchi M, Nicholson AG, GeisingerKR, Yatabe Y, et al. International association for the study oflung cancer/american thoracic society/european respiratorysociety international multidisciplinary classification of lungadenocarcinoma. J Thorac Oncol 2011;6:244-85.[Crossref]
• [8] Travis WD, Rekhtman N. Pathological diagnosis and classificationof lung cancer in small biopsies and cytology: strategicmanagement of tissue for molecular testing. Semin Respir CritCare Med 2011;32:22-31.[Crossref]
• [9] Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell2002;1:49-52.[Crossref]
• [10] Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, VogelS, et al. Identification of bronchioalveolar stem cells in normallung and lung cancer. Cell 2005;121:823-35.[Crossref]
• [11] Giangreco A, Groot KR, Janes SM. Lung cancer and lungstem cells: strange bedfellows? Am J Respir Crit Care Med2007;175:547-53.[Crossref]
• [12] Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identificationof novel genes coding for small expressed RNAs.Science 2001;294:853-8.[Crossref]
• [13] Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class oftiny RNAs with probable regulatory roles in Caenorhabditiselegans. Science 2001;294:858-62.[Crossref]
• [14] Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditiselegans. Science 2001;294:862-4.[Crossref]
• [15] Ambros V. The functions of animal microRNAs. Nature2004;431:350-5.
• [16] Hwang HW, Mendell JT. MicroRNAs in cell proliferation, celldeath, and tumorigenesis. Br J Cancer 2007;96 Suppl:R40-4.
• [17] Kim VN. MicroRNA biogenesis: coordinated cropping anddicing. Nat Rev Mol Cell Biol 2005;6:376-85.[Crossref]
• [18] Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates thenuclear export of pre-microRNAs and short hairpin RNAs. GenesDev 2003;17:3011-6.[Crossref]
• [19] Mingot JM, Bohnsack MT, Jakle U, Gorlich D. Exportin 7defines a novel general nuclear export pathway. EMBO J2004;23:3227-36.[Crossref]
• [20] Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclearexport of microRNA precursors. Science 2004;303:95-8.
• [21] Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. HumanRISC couples microRNA biogenesis and posttranscriptionalgene silencing. Cell 2005;123:631-40.[Crossref]
• [22] Carthew RW, Sontheimer EJ. Origins and Mechanisms ofmiRNAs and siRNAs. Cell 2009;136:642-55.[Crossref]
• [23] Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis,mechanism, function, and recent clinical trials. BiochimBiophys Acta;1803:1231-43.
• [24] He L, Hannon GJ. MicroRNAs: small RNAs with a big role in generegulation. Nat Rev Genet 2004;5:522-31.[Crossref]
• [25] Bartel DP. MicroRNAs: target recognition and regulatoryfunctions. Cell 2009;136:215-33.[Crossref]
• [26] Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R,Rajewsky N. Widespread changes in protein synthesis inducedby microRNAs. Nature 2008;455:58-63.
• [27] Baek D, Villen J, Shin C, Camargo FD, Gygi SP, BartelDP. The impact of microRNAs on protein output. Nature2008;455:64-71.
• [28] Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a rolein cancer. Nat Rev Cancer 2006;6:259-69.[Crossref]
• [29] Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y,Yanagisawa K, et al. Reduced expression of Dicer associatedwith poor prognosis in lung cancer patients. Cancer Sci2005;96:111-5.[Crossref]
• [30] Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. ImpairedmicroRNA processing enhances cellular transformation andtumorigenesis. Nat Genet 2007;39:673-7.[Crossref]
• [31] Jay C, Nemunaitis J, Chen P, Fulgham P, Tong AW. miRNAprofiling for diagnosis and prognosis of human cancer. DNACell Biol 2007;26:293-300.[Crossref]
• [32] Hu Z, Chen J, Tian T, Zhou X, Gu H, Xu L, et al. Genetic variantsof miRNA sequences and non-small cell lung cancer survival. JClin Invest 2008;118:2600-8.
• [33] Ranade AR, Cherba D, Sridhar S, Richardson P, Webb C, ParipatiA, et al. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small celllung cancer. J Thorac Oncol 2010;5:1273-8.[Crossref]
• [34] Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, YiM, et al. Unique microRNA molecular profiles in lung cancerdiagnosis and prognosis. Cancer cell 2006;9:189-98.[Crossref]
• [35] Wang XC, Tian LL, Wu HL, Jiang XY, Du LQ, Zhang H, et al.Expression of miRNA-130a in nonsmall cell lung cancer. Am JMed Sci 2010;340:385-8.
• [36] Silva J, Garcia V, Zaballos A, Provencio M, Lombardia L,Almonacid L, et al. Vesicle-related microRNAs in plasma ofNSCLC patients and correlation with survival. Eur Respir J 2010.
• [37] Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, NikitinAY. MicroRNA-34b and MicroRNA-34c are targets of p53and cooperate in control of cell proliferation and adhesionindependentgrowth. Cancer Res 2007;67:8433-8.
• [38] Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, ColburnNH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionallydownregulates tumor suppressor Pdcd4 and stimulatesinvasion, intravasation and metastasis in colorectal cancer.Oncogene 2008;27:2128-36.[Crossref]
• [39] Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko RJ, Jr., et al.microRNA-21 negatively regulates Cdc25A and cell cycleprogression in colon cancer cells. Cancer Res 2009;69:8157-65.[Crossref]
• [40] Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, ChowdhuryWH, et al. miR-21: an androgen receptor-regulated microRNAthat promotes hormone-dependent and hormone-independentprostate cancer growth. Cancer Res 2009;69:7165-9.[Crossref]
• [41] Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, HorikawaI, et al. MiR-21 is an EGFR-regulated anti-apoptotic factorin lung cancer in never-smokers. Proc Natl Acad Sci U S A2009;106:12085-90.[Crossref]
• [42] Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targetstumor suppressor genes in invasion and metastasis. Cell Res2008;18:350-9.[Crossref]
• [43] Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-DubyR, van Rooij E, et al. Modulation of K-Ras-dependent lungtumorigenesis by MicroRNA-21. Cancer cell 2010;18:282-93.[Crossref]
• [44] Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, etal. MicroRNA-21 promotes cell transformation by targeting theprogrammed cell death 4 gene. Oncogene 2008;27:4373-9.
• [45] Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, etal. MicroRNA-31 functions as an oncogenic microRNA in mouseand human lung cancer cells by repressing specific tumorsuppressors. J Clin Invest 2010;120:1298-309.[Crossref]
• [46] Xi S, Yang M, Tao Y, Xu H, Shan J, Inchauste S, et al. Cigarettesmoke induces C/EBP-beta-mediated activation of miR-31 innormal human respiratory epithelia and lung cancer cells. PLoSOne 2010;5:e13764.[Crossref]
• [47] Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, et al.Transgenic cyclin E triggers dysplasia and multiple pulmonaryadenocarcinomas. Proc Natl Acad Sci U S A 2007;104:4089-94.[Crossref]
• [48] Liu CJ, Tsai MM, Hung PS, Kao SY, Liu TY, Wu KJ, et al. miR-31ablates expression of the HIF regulatory factor FIH to activatethe HIF pathway in head and neck carcinoma. Cancer Res2010;70:1635-44.[Crossref]
• [49] Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA.Concurrent suppression of integrin alpha5, radixin, and RhoAphenocopies the effects of miR-31 on metastasis. Cancer Res2010;70:5147-54.[Crossref]
• [50] Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM,Wang ZC, et al. A pleiotropically acting microRNA, miR-31,inhibits breast cancer metastasis. Cell 2009;137:1032-46.[Crossref]
• [51] Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H,Endoh H, et al. Reduced expression of the let-7 microRNAsin human lung cancers in association with shortenedpostoperative survival. Cancer Res 2004;64:3753-6.[Crossref]
• [52] Inamura K, Togashi Y, Nomura K, Ninomiya H, HiramatsuM, Satoh Y, et al. let-7 microRNA expression is reduced inbronchioloalveolar carcinoma, a non-invasive carcinoma, andis not correlated with prognosis. Lung cancer 2007;58:392-6.[Crossref]
• [53] Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, et al.MicroRNA classifiers for predicting prognosis of squamous celllung cancer. Cancer Res 2009;69:5776-83.[Crossref]
• [54] Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T,Gel B, et al. miR-34a as a prognostic marker of relapse insurgically resected non-small-cell lung cancer. Carcinogenesis2009;30:1903-9.[Crossref]
• [55] Lodygin D, Tarasov V, Epanchintsev A, Berking C, KnyazevaT, Korner H, et al. Inactivation of miR-34a by aberrantCpG methylation in multiple types of cancer. Cell Cycle2008;7:2591-600.[Crossref]
• [56] He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D,Goodson S, et al. A microRNA polycistron as a potential humanoncogene. Nature 2005;435:828-33.
• [57] Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, et al.Widespread microRNA repression by Myc contributes to tumorigenesis.Nat Genet 2008;40:43-50.[Crossref]
• [58] Welch C, Chen Y, Stallings RL. MicroRNA-34a functions asa potential tumor suppressor by inducing apoptosis inneuroblastoma cells. Oncogene 2007;26:5017-22.[Crossref]
• [59] Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. TumorsuppressivemiR-34a induces senescence-like growth arrestthrough modulation of the E2F pathway in human colon cancercells. Proc Natl Acad Sci U S A 2007;104:15472-7.[Crossref]
• [60] Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE,et al. p53-mediated activation of miRNA34 candidate tumorsuppressorgenes. Curr Biol 2007;17:1298-307.[Crossref]
• [61] Zenz T, Mohr J, Eldering E, Kater AP, Buhler A, Kienle D, etal. miR-34a as part of the resistance network in chroniclymphocytic leukemia. Blood 2009;113:3801-8.[Crossref]
• [62] Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y,et al. Effects of miR-34a on cell growth and chemoresistancein prostate cancer PC3 cells. Biochem Biophys Res Commun2008;377:114-9.[Crossref]
• [63] Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, et al. Downregulation ofCCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett2008;582:1564-8.
• [64] He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. AmicroRNA component of the p53 tumour suppressor network.Nature 2007;447:1130-4.
• [65] Kong YW, Cannell IG, de Moor CH, Hill K, Garside PG, HamiltonTL, et al. The mechanism of micro-RNA-mediated translationrepression is determined by the promoter of the target gene.Proc Natl Acad Sci U S A 2008;105:8866-71.[Crossref]
• [66] Leucci E, Cocco M, Onnis A, De Falco G, van Cleef P, Bellan C,et al. MYC translocation-negative classical Burkitt lymphomacases: an alternative pathogenetic mechanism involving miRNAderegulation. J Pathol 2008;216:440-50. [Crossref]
• [67] Pigazzi M, Manara E, Baron E, Basso G. miR-34b targets cyclicAMP-responsive element binding protein in acute myeloidleukemia. Cancer Res 2009;69:2471-8.[Crossref]
• [68] Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repressionof SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A2008;105:13421-6.
• [69] Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, DragnevKH, et al. Uncovering growth-suppressive MicroRNAs in lungcancer. Clin Cancer Res 2009;15:1177-83.[Crossref]
• [70] Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, YendamuriS, et al. Human microRNA genes are frequently located atfragile sites and genomic regions involved in cancers. Proc NatlAcad Sci U S A 2004;101:2999-3004.[Crossref]
• [71] Lee YS, Dutta A. The tumor suppressor microRNA let-7represses the HMGA2 oncogene. Genes Dev 2007;21:1025-30.[Crossref]
• [72] Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, ChengA, et al. RAS is regulated by the let-7 microRNA family. Cell2005;120:635-47.[Crossref]
• [73] Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ. Highmobility group A2 is a target for miRNA-98 in head and necksquamous cell carcinoma. Mol Cancer 2007;6:5.[Crossref]
• [74] Koscianska E, Baev V, Skreka K, Oikonomaki K, RusinovV, Tabler M, et al. Prediction and preliminary validation ofoncogene regulation by miRNAs. BMC Mol Biol 2007;8:79.[Crossref]
• [75] Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M,Kelnar K, Ovcharenko D, et al. The let-7 microRNA repressescell proliferation pathways in human cells. Cancer Res2007;67:7713-22.[Crossref]
• [76] Dutt A, Wong KK. Mouse models of lung cancer. Clin Cancer Res2006;12:4396s-402s.[Crossref]
• [77] Meuwissen R, Berns A. Mouse models for human lung cancer.Genes Dev 2005;19:643-64.[Crossref]
• [78] Liu X, Sempere LF, Guo Y, Korc M, Kauppinen S, Freemantle SJ,et al. Involvement of microRNAs in lung cancer biology andtherapy. Translational research : the journal of laboratory andclinical medicine 2011;157:200-8.
• [79] Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS,Sharp PA, et al. Suppression of non-small cell lung tumordevelopment by the let-7 microRNA family. Proceedings of theNational Academy of Sciences of the United States of America2008;105:3903-8.
• [80] Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G. Agenetic mouse model for metastatic lung cancer with genderdifferences in survival. Oncogene 2007;26:6896-904.[Crossref]
• [81] Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, GoodallGJ, et al. Contextual extracellular cues promote tumor cellEMT and metastasis by regulating miR-200 family expression.Genes & development 2009;23:2140-51.
• [82] Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al.Frequent deletions and down-regulation of micro- RNA genesmiR15 and miR16 at 13q14 in chronic lymphocytic leukemia.Proceedings of the National Academy of Sciences of the UnitedStates of America 2002;99:15524-9.
• [83] Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D,et al. MicroRNA expression profiles classify human cancers.Nature 2005;435:834-8.
• [84] Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, et al.MicroRNA signature predicts survival and relapse in lungcancer. Cancer cell 2008;13:48-57.[Crossref]
• [85] Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, etal. MicroRNA expression differentiates histology and predictssurvival of lung cancer. Clin Cancer Res 2010;16:430-41.[Crossref]
• [86] Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, et al.Systematic analysis of microRNA expression of RNA extractedfrom fresh frozen and formalin-fixed paraffin-embeddedsamples. RNA 2007;13:1668-74.[Crossref]
• [87] Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV,Schwartz G, et al. Altered MicroRNA expression confined tospecific epithelial cell subpopulations in breast cancer. CancerRes 2007;67:11612-20.[Crossref]
• [88] Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumorderivedexosomes as diagnostic biomarkers of ovarian cancer.Gynecol Oncol 2008;110:13-21.[Crossref]
• [89] Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection ofsquamous cell lung cancer in sputum by a panel of microRNAmarkers. Mod Pathol 2010;23:1157-64.[Crossref]
• [90] Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, et al. Earlydetection of lung adenocarcinoma in sputum by a panel ofmicroRNA markers. International journal of cancer Journalinternational du cancer 2010;127:2870-8.[Crossref]
• [91] Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, et al. AlteredmiRNA expression in sputum for diagnosis of non-small celllung cancer. Lung cancer 2010;67:170-6.[Crossref]
• [92] Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterizationof microRNAs in serum: a novel class of biomarkersfor diagnosis of cancer and other diseases. Cell research2008;18:997-1006.[Crossref]
• [93] Keller A, Leidinger P, Borries A, Wendschlag A, WucherpfennigF, Scheffler M, et al. miRNAs in lung cancer - studying complexfingerprints in patient’s blood cells by microarray experiments.BMC cancer 2009;9:353.[Crossref]
• [94] Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, et al. PlasmamicroRNAs as potential biomarkers for non-small-cell lungcancer. Lab Invest 2011;91:579-87.[Crossref]
• [95] Hennessey PT, Sanford T, Choudhary A, Mydlarz WW, BrownD, Adai AT, et al. Serum microRNA biomarkers for detection ofnon-small cell lung cancer. PloS one 2012;7:e32307.[Crossref]
• [96] Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F,et al. MicroRNA signatures in tissues and plasma predictdevelopment and prognosis of computed tomography detectedlung cancer. Proceedings of the National Academy of Sciencesof the United States of America 2011;108:3713-8.
• [97] Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO.Exosome-mediated transfer of mRNAs and microRNAs is a novelmechanism of genetic exchange between cells. Nature cellbiology 2007;9:654-9.[Crossref]
• [98] Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, et al. Serum microRNAsignatures identified in a genome-wide serum microRNAexpression profiling predict survival of non-small-cell lungcancer. Journal of clinical oncology : official journal of theAmerican Society of Clinical Oncology 2010;28:1721-6.
• [99] Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection ofsquamous cell lung cancer in sputum by a panel of microRNAmarkers. Modern pathology : an official journal of theUnited States and Canadian Academy of Pathology, Inc2010;23:1157-64.
• [100] Tian T, Shu Y, Chen J, Hu Z, Xu L, Jin G, et al. A functionalgenetic variant in microRNA-196a2 is associated withincreased susceptibility of lung cancer in Chinese. Cancer epidemiology, biomarkers & prevention : a publication of theAmerican Association for Cancer Research, cosponsored bythe American Society of Preventive Oncology 2009;18:1183-7.
• [101] Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. ASNP in a let-7 microRNA complementary site in the KRAS 3’untranslated region increases non-small cell lung cancer risk.Cancer research 2008;68:8535-40.[Crossref]
• [102] Garzon R, Marcucci G, Croce CM. Targeting microRNAs incancer: rationale, strategies and challenges. Nature reviewsDrug discovery 2010;9:775-89.[Crossref]
• [103] miRview Lung: A microRNA-based Test to Identify LungTumor Type from Pre and Post Operative Samples.2012;www.mirnablog.com
• [104] Sempere LF, Liu X, Dmitrovsky E. Tumor-suppressivemicroRNAs in Lung cancer: diagnostic and therapeuticopportunities. The Scientific World Journal 2009;9:626-8.
• [105] Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, et al.Accumulation of miR-155 and BIC RNA in human B celllymphomas. Proc Natl Acad Sci U S A 2005;102:3627-32.[Crossref]
• [106] Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S,et al. MicroRNA gene expression deregulation in human breastcancer. Cancer Res 2005;65:7065-70.[Crossref]
• [107] Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, JacobsS, et al. BIC and miR-155 are highly expressed in Hodgkin,primary mediastinal and diffuse large B cell lymphomas. JPathol 2005;207:243-9.
• [108] Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A.High expression of precursor microRNA-155/BIC RNA inchildren with Burkitt lymphoma. Genes Chromosomes Cancer2004;39:167-9.
• [109] van den Berg A, Kroesen BJ, Kooistra K, de Jong D, Briggs J,Blokzijl T, et al. High expression of B-cell receptor induciblegene BIC in all subtypes of Hodgkin lymphoma. GenesChromosomes Cancer 2003;37:20-8.
• [110] Raver-Shapira N, Marciano E, Meiri E, Spector Y, RosenfeldN, Moskovits N, et al. Transcriptional activation ofmiR-34a contributes to p53-mediated apoptosis. Mol Cell2007;26:731-43.[Crossref]
• [111] Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluationof microRNA expression profiles that may predict recurrenceof localized stage I non-small cell lung cancer after surgicalresection. Cancer Res 2010;70:36-45.[Crossref]
• [112] Bader AG, Brown D, Stoudemire J, Lammers P. Developingtherapeutic microRNAs for cancer. Gene therapy2011;18:1121-6.[Crossref]
• [113] Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, etal. Combinatorial microRNA target predictions. Nat Genet2005;37:495-500.[Crossref]
• [114] Wu Y, Crawford M, Yu B, Mao Y, Nana-Sinkam SP, Lee LJ.MicroRNA delivery by cationic lipoplexes for lung cancertherapy. Molecular pharmaceutics 2011;8:1381-9.[Crossref]
• [115] Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, etal. Systemic delivery of tumor suppressor microRNA mimicsusing a neutral lipid emulsion inhibits lung tumors in mice.Mol Ther 2011;19:1116-22.[Crossref]
• [116] Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, BrownD, et al. Development of a lung cancer therapeutic basedon the tumor suppressor microRNA-34. Cancer research2010;70:5923-30.[Crossref]
• [117] Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T,Manoharan M, et al. Silencing of microRNAs in vivo with‘antagomirs’. Nature 2005;438:685-9.
• [118] Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, ChengA, Ford L, et al. The let-7 microRNA reduces tumor growth inmouse models of lung cancer. Cell Cycle 2008;7:759-64.[Crossref]
• [119] Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M,et al. Regression of murine lung tumors by the let-7 microRNA.Oncogene 2010;29:1580-7.[Crossref]
• [120] Gabriely G, Yi M, Narayan RS, Niers JM, Wurdinger T, ImitolaJ, et al. Human glioma growth is controlled by microRNA-10b.Cancer research 2011;71:3563-72.[Crossref]
• [121] Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG,et al. Therapeutic silencing of miR-10b inhibits metastasisin a mouse mammary tumor model. Nature biotechnology2010;28:341-7.[Crossref]
• [122] Lammers P. Mirna Therapeutics Secures $34.5 Million SeriesC Financing to Advance Oncology microRNA Pipeline into theClinic. 2012; www.businesswire.com
• [123] Zabludoff S. Therapeutic Areas of Regulus Therapeutics.2012;www.regulusrx.com

Identifiers

DOI

10.2478/micrnat-2014-0006